Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
V$438.91+2.32(+0.53%)Visa Just Raised Its Dividend 16%. Is It a Better Buy Than Mastercard?8:17:32 AM ETCVS$80.90+0.91(+1.14%)RPT-BREAKINGVIEWS-CVS’s problem: investors trust the warning label8:16:38 AM ETCOP$139.45+2.51(+1.83%)STAK Energy Signs Long-Term Agreement to Bring North Slope Natural Gas to Market8:15:00 AM ETMU$759.97-35.49(-4.46%)Is Micron stock a Buy after crashing below $800?8:13:57 AM ETGOOG$289.81+2.51(+0.87%)Meta Paid 1.4 Times What Alphabet Did to Borrow in Euros8:08:00 AM ETCOP$139.45+2.51(+1.83%)ConocoPhillips Profit Rises as Oil Prices Climb8:06:00 AM ETINTC$56.92-1.36(-2.33%)Intel: I Warned Before The 40% Crash, Now I'm Bullish (Rating Upgrade)8:05:00 AM ETASML$1,460.30-35.84(-2.40%)Could $10,000 Invested in ASML Set You Up for Life?8:05:00 AM ETAVGO$317.50-8.20(-2.52%)Broadcom Stock Could Be Approaching a Major Turning Point. Here's the Price Target8:03:07 AM ETVZ$46.70+0.53(+1.15%)Verizon Makes the Holidays Simple with Our Best Deals and Rewards Just for Being a Customer8:01:25 AM ETSHEL$102.84+0.98(+0.96%)Transaction in Own Shares8:00:53 AM ETIBM$256.39+2.07(+0.81%)IBM, AMD, Oak Ridge National Laboratory launch quantum error correction platform8:00:48 AM ETMETA$634.31+4.31(+0.68%)Voters rejected AI data centers over resource concerns. Here's why measuring water usage is hard8:00:01 AM ETISRG$484.18+1.99(+0.41%)World’s First Fully Robotic Transoral Gastric Procedures Completed Using EndoQuest’s Endoluminal Surgical System8:00:00 AM ETGOOG$289.81+2.51(+0.87%)Alphabet: Search Disruption Vs. The Rise Of Carbon8:00:00 AM ETAAPL$354.55+5.04(+1.44%)The new moto buds ultra 27 take audio up a notch with Sound by Bose technology and bring AI live translation to consumers8:00:00 AM ETTM$216.81+17.35(+8.70%)2027 Toyota Tundra: A Bold New Chapter in Full-Size Pickup Excellence with Advanced Towing Tech and the New Trailhunter Package8:00:00 AM ETIBM$256.39+2.07(+0.81%)Oak Ridge National Laboratory, IBM, and AMD Launch New Co-Design Platform for Quantum Error Correction8:00:00 AM ETNVDA$196.95-3.34(-1.67%)Nvidia Stock Is Back at $200. What History Suggests Is the Floor.7:57:00 AM ETAAPL$354.55+5.04(+1.44%)Apple: Demand Is Not The Problem7:54:50 AM ETCOP$139.45+2.51(+1.83%)BRIEF-ConocoPhillips Says Qatar LNG Production Remained Constrained Through Q37:50:36 AM ETMCD$280.65+0.43(+0.15%)McDonald's Is Rallying, but Can You Sleep at Night Owning It?7:48:44 AM ETPLTR$167.30-4.40(-2.56%)Palantir's CEO Just Said What Wall Street Doesn't Want to Hear About AI7:47:36 AM ETMSFT$557.50+1.70(+0.31%)The Same $10,000 in Microsoft and Meta Could Produce Very Different Results by 20307:47:14 AM ET

DYN · NASDAQ

Dyne Therapeutics, Inc.

$18.54 -0.02 (-0.11%)

Company overview

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$3.5B
Employees
192
Headquarters
Waltham, MA
Website
dyne-tx.com
CEO
John G. Cox
Listed
September 17, 2020
P/E
-5.76
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$1.1M
Operating income
-$471M
EBITDA
-$441M
Net income
-$452M
EPS
-$3.22
Total assets
$1.1B
Total debt
$19.3M
Earnings yield
-17.37%

Price chart

13.6017.1620.7224.2727.83
DYN 1D NASDAQ O18.57H19.00L17.94C18.56+0.51 (+2.83%)Vol3.20M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
DYNDyne Therapeutics, Inc. Stock news Dyne Therapeutics Q3 net loss widens on higher trial costs Reuters
DYNDyne Therapeutics, Inc. Press release Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights GlobeNewswire
DYNDyne Therapeutics, Inc. Stock news Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights GlobeNewswire
DYNDyne Therapeutics, Inc. Press release Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
DYNDyne Therapeutics, Inc. Press release Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) GlobeNewswire
DYNDyne Therapeutics, Inc. Press release Dyne Therapeutics Reports Inducement Grants Under Nasdaq GlobeNewswire
DYNDyne Therapeutics, Inc. Stock news Dyne Therapeutics, Inc. (DYN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
DYNDyne Therapeutics, Inc. Stock news Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class Seeking Alpha
DYNDyne Therapeutics, Inc. Stock news Stock Traders Buy High Volume of Dyne Therapeutics Call Options (NASDAQ:DYN) Defense World
DYNDyne Therapeutics, Inc. Stock news Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling Benzinga
DYNDyne Therapeutics, Inc. Stock news Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings Benzinga
DYNDyne Therapeutics, Inc. Stock news Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session Benzinga
DYNDyne Therapeutics, Inc. Stock news Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings GlobeNewswire
DYNDyne Therapeutics, Inc. Press release Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting GlobeNewswire
DYNDyne Therapeutics, Inc. Press release Dyne Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
DYNDyne Therapeutics, Inc. Stock news Fifth Third Bancorp Buys New Shares in Dyne Therapeutics, Inc. $DYN Defense World
DYNDyne Therapeutics, Inc. Stock news Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session Benzinga
DYNDyne Therapeutics, Inc. Stock news Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock GlobeNewswire
DYNDyne Therapeutics, Inc. Press release Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock GlobeNewswire
DYNDyne Therapeutics, Inc. Press release Dyne Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
See more
FAQ

Questions about Dyne Therapeutics, Inc.

What does Dyne Therapeutics, Inc. do?
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
What is DYN's market cap?
Dyne Therapeutics, Inc. (DYN) is a listed stock with a live quote. The latest market cap on this page is $3.5B.
Where is Dyne Therapeutics, Inc. headquartered?
Dyne Therapeutics, Inc. is headquartered in Waltham, MA.
How do I get DYN news from the API?
Call GET /v1/news?tickers=DYN. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does DYN news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for DYN, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the DYN price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs